Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Other solid neoplasm 1Gynecologic 1Genitourinary 1Dermatologic 1

Conditions

Pancreatic Neoplasms 70Breast Neoplasms 64Neoplasms 35Carcinoma, Non-Small-Cell Lung 29Neoplasm Metastasis 20Triple Negative Breast Neoplasms 18Lung Neoplasms 13Ovarian Neoplasms 12Adenocarcinoma 12Stomach Neoplasms 10Squamous Cell Carcinoma of Head and Neck 10Melanoma 10Head and Neck Neoplasms 8Fallopian Tube Neoplasms 7Cholangiocarcinoma 7Urinary Bladder Neoplasms 6Recurrence 6Esophageal Neoplasms 6Digestive System Neoplasms 5Colorectal Neoplasms 5Carcinoma, Ovarian Epithelial 5Uterine Cervical Neoplasms 4Sarcoma, Ewing 4Sarcoma 4Prostatic Neoplasms 4Parkinson Disease 4, Autosomal Dominant Lewy Body 4Pancreatic Diseases 4Inflammatory Breast Neoplasms 4Gallbladder Neoplasms 4Endocrine Gland Neoplasms 4

Interventions

Taxes 1Immunoglobulin G 1Disulfides 1Bevacizumab 1Albumin-Bound Paclitaxel 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Cervical Adenocarcinoma × Albumin-Bound Paclitaxel × Clear all
NCT02020707 2024-07-26

Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers

Mayo Clinic

Phase 1 Completed
43 enrolled
DermatologicGenitourinaryGynecologicOther solid neoplasmSarcoma

Cervical Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡